| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc. | Zunsemetinib (ATI-450-PsA-201) | Psoriatic arthritis | Phase 2a | Trial Discontinued | Oral | Immunology: Anti-TNF |
| Aclaris Therapeutics Inc. | ATI-502 (VITI-201 Topical) | Vitiligo | Phase 2 | Trial Discontinued | topical | N/A |
| Aclaris Therapeutics Inc. | ATI-502 (ATI-50002-AA-201) - dose ranging | Alopecia areata | Phase 2 | Topical | Immunology | |
| Aclaris Therapeutics Inc. | ATI-502 (VITI-201 Topical) | Vitiligo | Phase 2 | Trial Discontinued | topical | N/A |
| Aclaris Therapeutics Inc. | ATI-2138 | Atopic dermatitis (AD) | Phase 2a | Data Released | Oral | Immunology |
| Aclaris Therapeutics Inc. | ATI-502 (ATI-50002-AA-201) - dose ranging | Alopecia areata | Phase 2 | Topical | Immunology | |
| Acrivon Therapeutics Inc. | ACR-368 | Platinum-resistant ovarian,(PROC) endometrial, and urothelial cancers | Phase 2b | Data Released | Intravenous | Oncology |
| Actinium Pharmaceuticals Inc. | Actimab-A | Solid tumors | Phase 2/3 | Ongoing | Intravenous | Oncology |